Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.
The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
Company profile from EODHD, stored Oct 21, 2026.
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
No qualified FINRA settlements are stored in the last 240 days.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind CTY’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if CTY is in your portfolio and how much it contributes.
Sign inLoading market dates
Institutional coverage is still building for this ticker.
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: buy 19 days ago
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.